Dividends & Buybacks ·
Galmed Pharmaceuticals Ltd. announced a reverse stock split of its ordinary shares at a ratio of 1-for-8…
GLMDGalmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. announced a reverse stock split of its ordinary shares at a ratio of 1-for-8, consolidating eight pre-split shares into one post-split share with a par value increase from NIS 1.80 to NIS 14.40. The transaction is effective August 19, 2026, when trading resumes on the Nasdaq Capital Market under new CUSIP M47238205. Issued and outstanding shares will decrease from approximately 8,332,518 to roughly 1,041,565, with fractional shares rounded to the nearest whole share or cashed out if less than half a share remains. Outstanding warrants and options will receive proportionate adjustments to their exercise prices and share counts. The company operates in the biopharmaceutical industry, focusing on drug development.